In order to increase the chances of treatment success, it is important that patients are counseled about their condition and about realistic expectations for interstitial cystitis (IC) treatment.1 The information available here will help you counsel patients about IC and treating their bladder pain symptoms with
Patient Education Flyer
The flyer provides information to educate patients about IC, multimodal therapy with ELMIRON®, and helpful resources.
Download PDF
Download PDF
Journey to Relief®
Easy to enroll and absolutely FREE
An e-mail program developed exclusively for patients who
takeELMIRON® . The program delivers valuable patient
materials, including coupons, right to your patient's in-box.
For more information, please visit the
Journey to Relief® Web site.
An e-mail program developed exclusively for patients who
take
materials, including coupons, right to your patient's in-box.
For more information, please visit the
Journey to Relief® Web site.
Patient Education Slide Presentation & Invitation
This presentation, available in both PowerPoint and PDF formats, helps educate patients about IC, multimodal therapy with ELMIRON®, and appropriate lifestyle and diet modifications. The accompanying flyer invites patients to learn about IC.
Downloadable IC Etiology Animation
Download this tool to your desktop to help explain to your patients the etiology of IC and how ELMIRON® is believed to work.
Although the MOA of ELMIRON® is not fully understood, ELMIRON® is thought to adhere to the bladder mucosal lining, preventing potentially irritating solutes in the urine from reaching the bladder wall.
Download
Although the MOA of ELMIRON® is not fully understood, ELMIRON® is thought to adhere to the bladder mucosal lining, preventing potentially irritating solutes in the urine from reaching the bladder wall.
Download
(For Windows Compatible Systems Only)
- Reference:
- Kahn BS, Stanford EJ, Mishell DR Jr, Rosenberg MT, Wysocki S. Management
of patients with interstitial cystitis or chronic pelvic pain of bladder origin: a consensus report. Curr Med Res Opin. 2005;21:509-516.
Important Safety Information
- Contraindications: ELMIRON® is contraindicated in patients with known hypersensitivity to the drug, structurally related compounds, or excipients
- Anticoagulant Activity: ELMIRON® is a weak anticoagulant (blood thinner) which may increase bleeding. Patients undergoing invasive surgery or having signs/symptoms of underlying coagulopathy or other increased risk of bleeding (due to anticoagulant therapy or high doses of anti-inflammatory drugs) should be evaluated for the risk of hemorrhage
- Alopecia: In clinical trials of ELMIRON®, alopecia began within the first 4 weeks of treatment. Ninety-seven percent (97%) of the cases of alopecia reported were alopecia areata, limited to a single area on the scalp
- Use in Pregnancy: ELMIRON® is a Pregnancy Category B drug
- Most Common Adverse Reactions (frequency 1% to 4%): Alopecia (4%), diarrhea (4%), nausea (4%), headache (3%), rash (3%), dyspepsia (2%), abdominal pain (2%), liver function abnormalities (1%), dizziness (1%)